Overview
Dysplasia epiphysealis hemimelica (DEH), also known as Trevor disease or tarso-epiphyseal aclasis, is a rare developmental skeletal disorder characterized by asymmetric overgrowth of cartilage affecting one or more epiphyses (the ends of long bones) on one side of the body. The condition predominantly affects the lower extremities, most commonly involving the ankle (talus), knee (distal femur or proximal tibia), and hip joints. The overgrowth typically occurs on the medial (inner) side of the affected limb, though lateral involvement has also been reported. The condition is roughly three times more common in males than females. Clinically, patients present with painless swelling or a hard mass near an affected joint, often noticed in early childhood. As the abnormal cartilaginous overgrowth progresses, it can lead to joint pain, restricted range of motion, limb length discrepancy, angular deformity (such as valgus or varus), and gait abnormalities. The disease may be classified as localized (affecting a single epiphysis), classic (involving multiple epiphyses in a single limb), or generalized (affecting an entire lower extremity). Radiographic imaging reveals irregular, lobulated ossification arising from the epiphysis, and MRI can help delineate the cartilaginous component. There is no known medical treatment for DEH. Management is primarily surgical and is indicated when the overgrowth causes pain, functional limitation, or significant deformity. Surgical excision of the osteocartilaginous mass is the standard approach, with the goal of preserving joint function and correcting alignment. Recurrence after surgery is possible, particularly in younger children with significant remaining growth. Long-term outcomes are generally favorable when the condition is identified early and managed appropriately, though secondary osteoarthritis may develop in affected joints over time.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Dysplasia epiphysealis hemimelica.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Dysplasia epiphysealis hemimelica at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Dysplasia epiphysealis hemimelica.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Dysplasia epiphysealis hemimelica.
Community
No community posts yet. Be the first to share your experience with Dysplasia epiphysealis hemimelica.
Start the conversation →Latest news about Dysplasia epiphysealis hemimelica
No recent news articles for Dysplasia epiphysealis hemimelica.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Dysplasia epiphysealis hemimelica
What is Dysplasia epiphysealis hemimelica?
Dysplasia epiphysealis hemimelica (DEH), also known as Trevor disease or tarso-epiphyseal aclasis, is a rare developmental skeletal disorder characterized by asymmetric overgrowth of cartilage affecting one or more epiphyses (the ends of long bones) on one side of the body. The condition predominantly affects the lower extremities, most commonly involving the ankle (talus), knee (distal femur or proximal tibia), and hip joints. The overgrowth typically occurs on the medial (inner) side of the affected limb, though lateral involvement has also been reported. The condition is roughly three times
How is Dysplasia epiphysealis hemimelica inherited?
Dysplasia epiphysealis hemimelica follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Dysplasia epiphysealis hemimelica typically begin?
Typical onset of Dysplasia epiphysealis hemimelica is childhood. Age of onset can vary across affected individuals.